Entries by primitus

LSX World Congress

4-5 February, 2020 LSX World Congress London, UK Team members attending: Dr Giuseppe Mazza, CEO [panel speaker]

Cirrhotic Human Liver Extracellular Matrix 3D Scaffolds Promote Smad-Dependent TGF-β1 Epithelial Mesenchymal Transition

January 2020 Cirrhotic Human Liver Extracellular Matrix 3D Scaffolds Promote Smad-Dependent TGF-β1 Epithelial Mesenchymal Transition Mazza. G, Telese. A, Al-Akkad. W, Frenguelli. L, Levi. A, Marrali. M, Longato. L, Thanapirom. K, Vilia. M.G, Lombardi. B, Crowley. C, Crawford. M, Karsdal. M.A, Leeming. D.J, Marrone. G, Bottcher. K, Robinson. B, Del Rio Hernandez. A, Tamburrino. D, […]

Engitix and Morphic Enter Research Collaboration to Identify ECM-related Targets in Fibrostenotic Inflammatory Bowel Disease (IBD)

London, UK and Waltham, Massachusetts, USA – 10 December, 2019 – Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, and Morphic Therapeutic (‘Morphic’), a biopharmaceutical company developing oral integrin therapies, today announce that they have entered into a research […]

Engitix Receives a Golden Ticket to LabCentral from Takeda to Advance Fibrosis and Solid Tumour Research

Golden Ticket includes one year of lab bench space at Cambridge, MA-based shared laboratory and office space London, UK, 5 November 2019 – Engitix Ltd (‘Engitix’), a private company focused on drug discovery for fibrosis and solid tumours based on its pioneering human extracellular matrix (ECM) platform, announced that its subsidiary Engitix, Inc, has been awarded a Golden Ticket […]